Insilico Medicine advances AI drug for IPF to Phase III trials
Insilico Medicine is advancing to Phase III human trials for testing a drug identified by AI targeting idiopathic pulmonary fibrosis (IPF). This progression supplies the computational drug discovery sector
Read More